Pharma and biotech M&A is set to slow globally in 2016
After a feversih 2015, a convergence of factors may cool M&A activity in the sector this year
You must be signed in to read this analysis
In this article
- M&A drivers
- Specialty pharmaceuticals
- Tax inversions
What is this?
This article is from the Oxford Analytica Daily Brief, which analyses geopolitical, economic, social, business and industrial developments on a global and regional basis, providing clients with timely, authoritative analysis every business day of the year. Find out more about the Oxford Analytica Daily Brief, or request a trial.
